Home > Research > Publications & Outputs > Osteonectin as a screening marker for pancreati...


Text available via DOI:

View graph of relations

Osteonectin as a screening marker for pancreatic cancer: A prospective study

Research output: Contribution to journalJournal articlepeer-review

  • Angeliki Papapanagiotou
  • George Sgourakis
  • Kyriakos Karkoulias
  • Dimitris Raptis
  • Edward Thomas Parkin
  • Pantelis Brotzakis
  • Sanjay Panchal
  • Athanasios Papavassiliou
<mark>Journal publication date</mark>1/07/2018
<mark>Journal</mark>Journal of International Medical Research
Issue number7
Number of pages11
Pages (from-to)2769-2779
Publication StatusPublished
Early online date13/05/18
<mark>Original language</mark>English


ObjectiveOsteonectin plays a central role in various processes during the development of pancreatic adenocarcinoma. This prospective pilot study was performed to determine the feasibility of serum osteonectin as a screening tool for pancreatic cancer.
MethodsBlood samples were collected from 15 consecutive patients with newly diagnosed pancreatic cancer and 30 matched healthy controls. Serum osteonectin was measured using an osteonectin enzyme-linked immunosorbent assay kit. The primary outcomes were the diagnostic performance of serum osteonectin and the threshold value for differentiation of patients from controls.
ResultsThe median/quartile range of serum osteonectin in patients and controls were 306.8/288.5 ng/mL and 67.5/39.8 ng/mL, respectively. Osteonectin concentrations significantly differed among the study groups. A plasma osteonectin concentration of >100.18 ng/mL as selected by the receiver operating characteristic curves demonstrated an estimated area under the curve of 86% for prediction of pancreatic cancer. Tumour size was a significant predictor of serum osteonectin. A statistically significant difference in serum osteonectin between T1/T2 and T3/T4 tumours was found. Post-hoc comparisons revealed statistically significant differences in the serum osteonectin among the control, T1/T2, and T3/T4 groups.
ConclusionOsteonectin may be used as a screening tool for pancreatic cancer, although this must be validated in prospective studies.